Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4593244 | 0.89 | TLR8 (0.57) | TLR8TLR7 | |
| SCHEMBL27649971 | 0.85 | TLR7 (0.51) | TLR8TLR7 | |
| SCHEMBL4080325 | 0.84 | TLR8 (0.54) | TLR8TLR7 | |
| SCHEMBL1960130 | 0.81 | TLR7 (0.70) | TLR8TLR7 | |
| SCHEMBL3865842 | 0.81 | TLR7 (0.54) | TLR8TLR7 | |
| SCHEMBL27649940 | 0.81 | LMNA (0.39) | TLR8TLR7 | |
| SCHEMBL12003054 | 0.81 | TLR8 (0.68) | TLR8TLR7 | |
| SCHEMBL29034534 | 0.81 | TLR7 (0.71) | TLR8TLR7 | |
| SCHEMBL3876362 | 0.80 | TLR7 (0.57) | TLR8TLR7 | |
| SCHEMBL5461944 | 0.80 | TLR7 (0.58) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685129-A4 | OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M INNOVATIVE PROPERTIES CO (US) | 2008-10-22 | — | — | EP | disclosed |
| CN-1906193-A | Oxime substituted imidazo ring compounds | 3M INNOVATIVE PROPERTIES CO (US) | 2007-01-31 | — | — | CN | disclosed |
| CN-1906192-A | Hydroxylamine substituted imidazo ring compounds | 3M INNOVATIVE PROPERTIES CO (US) | 2007-01-31 | — | — | CN | disclosed |
| EP-1685129-A2 | OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M Innovative Properties Company (US) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005048933-A2 | OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |